| Vol. 23.09 – 21 March, 2022 |
| |
|
|
| Scientists reported results from an in-human Phase I trial of castration-resistant, prostate cancer-directed CAR T cells armored with a dominant-negative transforming growth factor (TGF)- receptor [Nature Medicine] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators showed that higher intratumoral frequencies of γδ T cells, which have potential for HLA-unrestricted tumor reactivity, associated with enhanced hepatocellular carcinoma patient survival. [Nature Communications] |
|
|
|
| The authors established a TRUE CAR-T cell therapeutic modality, in which exogenous antigens were loaded onto fusogenic nanoparticles to achieve in situ modification of cell membrane in solid tumors, providing targets for subsequent CAR-T cell therapy. [Journal of Hematology & Oncology] |
|
|
|
| Scientists demonstrated that ex vivo lentivirus-modified, rapamycin-conditioned CD4+ T cells could also act as next-generation cellular delivery vehicles—that is, “micropharmacies”—to disseminate corrective enzymes for multiple lysosomal storage disorders. [EMBO Molecular Medicine] |
|
|
|
| The authors studied transplant outcomes in severe combined immunodeficiency (SCID) infants according to donor type, specifically TCRαβ/CD19-depleted haploidentical family donor transplant, and conditioning, through retrospective cohort analysis of 52 consecutive infants with SCID transplanted. [Journal of Clinical Immunology] |
|
|
|
| Investigators leveraged on the lentiviral vector (LV)-mediated intracerebral gene therapy platform to deliver Hex genes to the CNS and combined this strategy with bone marrow transplantation to provide a timely, pervasive, and long-lasting source of the Hex enzyme in the CNS and periphery of Sandhoff disease mice. [Molecular Therapy-Methods & Clinical Development] |
|
|
|
| Researchers evaluated the functionality of mRNA-engineered dual-CAR natural killer (NK)-92 against tumor B cell lines and primary patient samples. [Journal of Translational Medicine] |
|
|
|
| With the aim of designing a preclinical study evaluating an intracerebral cell-based therapy for stroke, an observational study was performed in the rat suture model of ischemic stroke. [Scientific Reports] |
|
|
|
| The authors evaluated the capacity of allogeneic mesenchymal stromal cells to induce dental-pulp and apical bone regeneration in a tooth previously endodontically treated. [Journal of Endodontics] |
|
|
|
|
| Investigators set out the challenges associated with the clinical translation of cell therapy, using Huntington’s disease as a specific example, and suggest potential strategies to address these challenges. [Brain] |
|
|
|
| Scientists provide an updated review and future perspectives on features of the tumor microenvironment that represent barriers to CART cell therapy efficacy, including competition for metabolic fuels, physical barriers to infiltration, and immunosuppressive factors. [Molecular Therapy Oncolytics] |
|
|
|
| The authors discuss recent advances in understanding the mechanisms that regulate stem cell regeneration. [Stem Cells Translational Medicine] |
|
|
|
|
| Enochian BioSciences issued an exclusive sub-license of one of its proprietary technologies that could improve the effectiveness of a potential cure for HIV with an anti-HIV CAR-T therapy that Caring Cross is studying in a clinical trial. [Enochian BioSciences] |
|
|
|
| I Peace, Inc. announced that the company had tripled its capacity to manufacture GMP grade iPSCs and iPSC-derived differentiated cells by expanding its facility. [I Peace, Inc.] |
|
|
|
|
| May 5 – 8, 2022 Boston, Massachusetts, United States |
|
|
|
|
|
| Seattle, Washington, United States – Fred Hutchinson Cancer Research Center |
|
|
|
| Aspect Biosystems – Vancouver, British Columbia, Canada |
|
|
|
| Institute of Cancer Research – London, England, United Kingdom |
|
|
|
| BioNTech – Gaithersburg, Maryland, United States |
|
|
|
| Friedrich Miescher Institute for Biomedical Research – Basel, Switzerland |
|
|
|
|